Istesso’s Idiopathic Pulmonary Fibrosis Candidate Gains Fast Track
The FDA has granted Fast Track status to UK-based Istesso’s BS2320 drug candidate for the treatment of patients with idiopathic pulmonary fibrosis (IPF), a chronic disease that causes lung scarring.
BS2320 is a metabolic reprogramming agent that has already shown promise in reducing symptoms and remodeling fibrotic tissue in rheumatoid arthritis patients.
The company plans to launch a clinical study in IPF patients beginning in 2023. BS2320 has also received Orphan Drug status for treatment of IPF.
The Fast Track designation is designed to expedite reviews of drugs to treat serious conditions and fill an unmet medical need.
About Istesso
Istesso is a drug discovery and development company working in the field of immunometabolism. Istesso pipeline of pre-clinical and clinical assets act by reprogramming metabolism to treat autoimmune and inflammatory conditions such as rheumatoid arthritis and multiple sclerosis. Istesso was founded in 2017 as the holding company for Modern Biosciences Ltd.
December 12, 2022
